格隆汇8月11日|据默沙东中国消息,默沙东普瑞明®(来特莫韦)两种剂型获批新增200天剂量方案,对异基因造血干细胞移植(HSCT)后有巨细胞病毒(CMV)感染风险的成人患者可将预防用药时间延长至HSCT后200天。此前获批的成人和儿童患者持续用药时间为至HSCT后100天,此次延长成人患者给药时间方案的获批,将为有迟发性CMV感染和CMV病风险的成人患者提供更长时间的CMV感染预防守护。
Source Link格隆汇8月11日|据默沙东中国消息,默沙东普瑞明®(来特莫韦)两种剂型获批新增200天剂量方案,对异基因造血干细胞移植(HSCT)后有巨细胞病毒(CMV)感染风险的成人患者可将预防用药时间延长至HSCT后200天。此前获批的成人和儿童患者持续用药时间为至HSCT后100天,此次延长成人患者给药时间方案的获批,将为有迟发性CMV感染和CMV病风险的成人患者提供更长时间的CMV感染预防守护。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.